Company ProfilePremium

Hygrovest Limited

Company Profile Analysis

Ticker: UWC.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Hygrovest Limited - Company showcase

Year Founded & Workforce

2014

1 Employees

Hygrovest Limited logo

Hygrovest Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Hygrovest Limited Overview

Underwood Capital Limited is a Sydney-based, ASX-listed specialist investment company that has spent the last decade evolving from a vertically integrated medical-cannabis venture (Phytotech Medical, 2015) into a diversified, value-oriented small-cap investment vehicle. From 2018 to 2023, as MMJ Group Holdings and then Hygrovest, it was Australia's principal listed vehicle for minority investments in North American cannabis companies, an exposure that produced cumulative losses exceeding A$60 million over FY2020–FY2023. Since 1 July 2023 the portfolio has been managed by HD Capital Partners, which has liquidated nearly all legacy cannabis assets and redeployed capital into concentrated positions in cash-generative, ASX-listed business-to-business service and software companies. At 30 June 2026 the company held A$13.5m of listed securities, A$0.7m cash and a A$7.0m stake in Canadian cannabis producer Weed Me Inc., its final legacy asset. The shares trade at roughly a 40–45% discount to post-tax NTA, below the value of its liquid assets alone.


Company's own description

The FY2026 Annual Report describes the principal activity as follows (paraphrased closely to preserve meaning): UWC is an Australian-listed specialist investment company that has traded on the ASX since 2015; investors gain exposure to a portfolio that primarily seeks to produce capital growth over the medium term from investments in listed and unlisted equities and debt securities. Investments are managed by HD Capital Partners under an Investment Management Agreement running from 1 July 2023 to 30 June 2028. The company measures and evaluates substantially all investments on a fair value basis.

The FY2026 Directors' Report adds a stated goal: to significantly outperform global equity markets over rolling five-year periods by taking concentrated, long-term positions in undervalued and overlooked companies while prioritising protection of capital.

Aggregator profiles of the HD Capital mandate (Pearler, based on company disclosures) describe three target categories: undervalued, well-managed growth companies, often founder-led, that are off the radar of the broader investment community; undervalued securities where the company seeks to realise value; and special situations dependent on a corporate action such as mergers, liquidations, tender offers and divestments.

Business model and "revenue" model

Income componentFY2025 (AUD K)FY2026 (AUD K)Nature
Interest and dividend income540427Recurring cash yield from listed holdings, the AAA cash ETF and (in FY2026) dividends from Weed Me
Net unrealised gains/(losses) on financial instruments at FVTPL1,529(698)Mark-to-market; non-cash, volatile
Realised gains/(losses) on disposal(1,216)955Crystallised on sale
Other operating income830Non-recurring
Total income936684—

Underwood has no products, services, subscriptions or licensing. Its "revenue" (reported as total income) comprises three components, all arising from the investment portfolio:

Source: UWC FY2026 Annual Report, Statement of Profit or Loss. (The Appendix 4E headline shows FY2025 revenue as 937; the statement shows 936 — a rounding difference.)

Costs comprise investment management fees (1% p.a. of pre-tax NAV, plus a 20% performance fee above a 6% hurdle and high-water mark), employee and director costs, and administration and listing costs. Value creation for shareholders is therefore a function of (a) gross portfolio returns, (b) the cost ratio, (c) tax, and (d) the market's discount to NTA, which the company is attempting to arbitrage through on-market buybacks.

Value chain position, customers and end-markets

As an LIC, Underwood sits at the capital-provider end of the value chain: it supplies permanent equity capital to listed small caps (by buying in the secondary market) and, historically, growth capital to private cannabis companies. Its "customers" are its shareholders — 2,623 holders at 21 July 2026, predominantly retail and self-managed superannuation funds, with the manager's principals and associates among the largest holders. Its end-markets are the companies it owns: at 30 June 2026, ASX-listed B2B services and software (Airtasker, Kip McGrath Education Centres, Cuscal, Fiducian Group, Cogstate, LaserBond, Praemium, ReadyTech, Reckon), a cash ETF (Betashares AAA), and Canadian adult-use cannabis consumer packaged goods (Weed Me Inc.).

Independent characterisation

Underwood is best understood as a sub-scale, closed-end value fund in transition. The strategic story has three acts. Act one (2015–2018) was an operating medical-cannabis company (Phytotech) that pivoted to an investment holding model after Harvest One diluted it out of control. Act two (2018–2023) was a thematic cannabis investment company managed from Canada by Parallax Ventures, which suffered heavily from the 2019–2023 collapse in Canadian cannabis valuations; NTA fell from roughly 20.5c per share in March 2021 to about 9.2c by June 2023, with an unmarketable-parcel buyback and a cost-cutting program following. Act three (July 2023 onward) is a value-investing turnaround under HD Capital Partners: liquidate legacy illiquids, cut costs, buy back stock at a discount, and compound in concentrated ASX small caps.

The key structural problem is scale. With roughly A$19m of net assets and operating costs of A$0.84m in FY2026 (about 4.4% of average net assets), the vehicle needs a gross return of roughly 4–5% just to stand still before tax. The key structural opportunity is the discount: the share price (about 5.4c) sits below the value of cash and listed securities alone (about 6.9c per share pre-tax), so investors are effectively being paid to take the Weed Me stake.

Strategy

Stated strategy (themes from FY2024 and FY2026 Annual Reports)

The board's three-pillar improvement program, first articulated in FY2024 and reaffirmed in FY2026, is:

  1. Maximise the value of existing investments — realise legacy cannabis assets "in a rational and patient manner" and only when in shareholders' interests (Proactive summary of October 2024 investment report).

  2. Maintain a value-focused investment approach — concentrated, long-term positions in undervalued and overlooked companies, with explicit emphasis on downside protection and "what can go wrong".

  3. Minimise fixed costs — the explicit cost program delivered a 46% fall in operating expenses over FY2023–FY2026.

The overarching objective is to significantly outperform global equity markets over rolling five-year periods.

The FY2026 manager letter adds investment-style themes: preference for mission-critical products and services with predictable revenues and strong free cash flow (which skews the portfolio toward technology); a view that, in the short term, AI is more likely to benefit entrenched software businesses through lower costs and faster development, but that the long-run impact is unknowable; and a deliberate focus on "easier games" in market corners others cannot or will not fish in.

Initiatives in the last 24 months (Oct 2024 – Oct 2026)

InitiativeDateDetailStatus
Rebrand to Underwood CapitalDec 2024Removes cannabis association ("Hygrovest"); new ticker UWC and website uwcl.com.auComplete
Legacy asset liquidationSep–Oct 2024ETG sold for A$3.8m; Delivra sold for about C$1.1mComplete; Weed Me remains
Weed Me monetisationOngoingManager publicly invites approaches from acquirers for the stake (FY2026 letter)Active
On-market buyback #1Sep 2024 – Oct 2025Up to 21,031,060 shares; capped at 105% of 5-day VWAPExpired; small volumes executed
On-market buyback #2From 10 Apr 2026Up to about 20,532,686 shares; 1,796,057 bought at an average A$0.0525 by 30 Jun 2026Active. TipRanks reports an Appendix 3C update extending a buyback to 27 Oct 2026 — the relationship between this update and the March 2026 program is unclear from available sources
Unmarketable-parcel buybacksJun 2023; FY202519.64m shares (A$1.04m) and 4.57m shares (A$0.23m) cancelled; holders with unmarketable parcels fell from 1,311 (Aug 2024) to 535 (Jul 2026)Complete
Corporate simplificationDec 2025UK subsidiary deregisteredComplete
Audit cost reductionMar 2024; Mar 2026Two auditor changes; total audit fees fell from A$114k (FY2023) to A$52k (FY2026)Complete

Medium-term targets and guidance

No quantitative financial guidance or medium-term targets are published. The only explicit operating target disclosed was the FY2024 forecast that non-management-fee operating costs would fall from more than A$1.3m (FY2023) to around A$0.7m (FY2025). ESG or sustainability commitments: none disclosed. The company states the performance of its portfolio is materially dependent on overall global equity market performance.

Products & Services

Underwood sells no products or services. The functional equivalent of a product catalogue for an LIC is its investment portfolio, which is what shareholders buy exposure to. The complete disclosed holdings list (ASX Listing Rule 4.10.20) follows.

Holdings at 30 June 2026 (FY2026 Annual Report)

HoldingTypeExchange / domicileDescription (analyst characterisation)
Weed Me Inc.Unlisted equityCanadaLicensed Canadian cannabis producer focused on convenience-category brands; book value A$6.982m; reported record sales and paid a dividend in 2026 per its CEO
Betashares Australian High Interest Cash ETF (AAA)Listed ETFASXCash-equivalent liquidity reserve; A$0.388m
Airtasker Ltd (ART)Listed equityASXOnline services marketplace
Kip McGrath Education Centres Ltd (KME)Listed equityASXTutoring franchise network
Cuscal Ltd (CCL)Listed equityASXPayments and banking infrastructure provider
Fiducian Group Ltd (FID)Listed equityASXFinancial planning and platform administration
Cogstate Ltd (CGS)Listed equityASXCognitive assessment technology for clinical trials and healthcare
LaserBond Ltd (LBL)Listed equityASXSurface engineering and wear-protection services
Praemium Ltd (PPS)Listed equityASXInvestment platform and portfolio administration software
ReadyTech Holdings Ltd (RDY)Listed equityASXMission-critical SaaS for education, workforce and government
Reckon Ltd (RKN)Listed equityASXAccounting and practice-management software
GM Health Group Pty LtdUnlisted equityAustraliaLegacy small unlisted holding; value not separately disclosed (believed immaterial)

Aggregate listed equities excluding AAA: A$13.104m. Individual position sizes are not publicly disclosed in the annual report. The manager states the listed book consists entirely of ASX-listed B2B service companies purchased at low multiples of normalised free cash flow (FY2026 Investment Manager Report).

Holdings at 30 June 2024 (FY2024 Annual Report) — for comparison

HoldingTypeValue AUD K (where disclosed)
Weed Me Inc. (equity)Unlisted9,171
Emerging Therapeutics Group (formerly Southern Cannabis Holdings)Unlisted3,993
Delivra Health Brands (formerly Harvest One)Listed TSX-V2,131
Valo Therapeutics Oy (convertible/loan)Unlisted, Finland600
Sequoya Cannabis (convertible/loan)Unlisted, Canada247
Other listed securities (Ainsworth Game Technology, Airtasker, BevCanna Enterprises, Centrepoint Alliance, Fiducian, Praemium, Reckon, Reklaim, Vintage Wine Estates, AAA ETF)Listed4,647
Other unlisted (Bespoke A LP, Bowery Capital Mortgage & Investment Fund, Eildon Debt Fund, GM Health Group)Unlisted754

Investment management "service terms" (the price shareholders pay)

TermDetail
ManagerHD Capital Partners Pty Ltd (principals who signed the FY2026 manager letter: Daniel Sims and Harley Grosser)
Term5 years, 1 Jul 2023 – 30 Jun 2028
Base fee1.0% p.a. (plus GST) of pre-tax NAV, paid monthly
Performance fee20% (plus GST) of pre-tax NAV above the high-water mark compounded at a 6% p.a. hurdle, adjusted for capital flows; nil if portfolio value falls
Base fees paidFY2024 A$171,287; FY2026 A$249,287 (FY2025 not separately extracted; asset management expenses A$211k)
Performance fees paidNil in FY2024, FY2025 and FY2026
PredecessorParallax Ventures Inc. (Canada), base fees A$188,608 in FY2023, no performance fee

Financial Narrative

Income statement (A$000 unless stated)

Sources: FY2024 Annual Report (FY2022–FY2024 five-year table and income statement); FY2026 Annual Report (FY2025–FY2026). "n/d" = not disclosed in the documents obtained.

Longer history for context: FY2020 total income -41,258, NPAT -40,082, EPS -17.61c; FY2021 total income -5,184, NPAT -4,024, EPS -1.75c (FY2024 Annual Report). FY2019 net profit A$21.6m (Barchart; aggregator).

Operating expense detail

Sources: FY2024 and FY2026 Annual Reports.

Margins and growth

Analyst calculations. Margins on total income are of limited interpretive value because "revenue" includes mark-to-market movements; the expense ratio is the more relevant efficiency metric. NPAT exceeds PBT in FY2025 and FY2026 because of tax benefits from deferred-tax reversals and reconciling items.

Balance sheet (A$000 at 30 June)

Sources and derivations: FY2023–FY2024 from FY2024 Annual Report balance sheet. FY2025 from FY2026 Annual Report parent-entity note (total assets 21,708; liabilities 2,478; current liabilities 530). FY2022 total assets from Barchart (aggregator; reported in thousands — figure consistent with AUD filings), FY2022 cash and financial assets from FY2023 opening balances, FY2022 equity from the FY2024 statement of changes in equity; FY2022 liabilities and NTA per share derived. FY2026 total assets derived by the analyst as the sum of disclosed asset lines (cash 697 + receivables 71 + financial assets 20,473 + DTA 20); FY2026 total liabilities derived as total assets less equity — both are approximations, the full FY2026 balance sheet table was not extractable. FY2026 NTA per share is as reported (9.46c).

Cash flow (A$000)

Sources: FY2024 and FY2026 Annual Reports, statements of cash flows. Because the company is an investment entity, purchases and sales of investments are classified in operating cash flow, which makes OCF and FCF reflect portfolio rotation rather than "earnings quality". A more meaningful measure is net cash cost of running the vehicle (payments to employees and suppliers less dividends and interest received): FY2023 about -1.02m; FY2024 about -0.95m; FY2025 about -0.37m; FY2026 about -0.41m.

Ratios

Analyst calculations from the tables above. Price / NTA uses the 30 June closing share prices reported in the remuneration-report TSR tables (FY2022 0.064; FY2023 0.042; FY2024 0.046; FY2025 0.046; FY2026 0.054) divided by reported or derived NTA per share.

Commentary on trends, inflections and drivers

FY2020–FY2022: value destruction. The cumulative net loss over FY2020–FY2022 was about A$60m, driven by the collapse of Canadian cannabis valuations after the 2018 legalisation boom. The FY2021 Annual Report notes the portfolio had a significant unlisted bias (listed assets were only 27% of NAV), and several unlisted investees deferred IPO plans, leaving MMJ unable to realise value while its listed benchmark rallied on IPO and merger activity. Total assets fell from about A$95.7m (FY2019, aggregator) to A$26.4m by FY2022.

FY2023: the bottom and the reset. A further A$4.0m loss (dominated by A$2.8m of unrealised write-downs) took NTA per share to 9.18c. The board responded decisively: it tendered the management mandate, ended the Parallax relationship, renewed the board with value-investing and governance expertise (Sauer, Prescott), and executed a A$1.04m unmarketable-parcel buyback that cancelled 19.6m shares and reduced registry costs.

FY2024: transition year. Net result was a small loss (A$0.13m) as gains on Delivra (+A$1.5m), ETG (+A$0.6m) and Weed Me (+A$0.4m) were almost entirely offset by the Medio Labs write-off (-A$1.96m). Operating expenses fell 30% to A$1.10m. Crucially, cash was deployed: payments for investments of A$5.0m took cash from A$3.7m to A$0.2m and lifted listed holdings from A$0.8m to A$6.8m.

FY2025: liquidation and redeployment. The ETG sale (A$3.8m), the Delivra sale (about C$1.1m) and the Sequoya and Valo realisations converted almost all residual illiquids to cash, which was recycled into ASX listings (A$14.0m of purchases and A$14.8m of disposals, indicating active rotation). The company recorded its first profit under the new manager (A$0.24m), helped by a A$0.2m tax benefit.

FY2026: two halves. NTA rose strongly to 10.89c in the December half (H1 revenue up 356% and profit up 460% year on year, per InvestSMART's summary of the half-year report), then gave back much of the gain in the March quarter, which the manager attributes to a global sell-off in software stocks it calls the "SaaSpocalypse". Full-year profit was A$0.19m. The listed book gained A$2.49m (about 22.9% gross on opening listed capital, per the manager), but Weed Me was written down A$1.80m, from A$8.86m to A$6.98m, despite the investee reporting record sales and paying a dividend. NTA per share rose to 9.46c, aided by buybacks.

Cost discipline is the clearest positive trend. Operating expenses fell from A$1.57m (FY2023) to A$0.84m (FY2026), a 46% reduction, consistent with the board's FY2024 forecast of non-management-fee costs falling to around A$0.7m. CFO base salary was cut from A$225,000 to A$170,000.

The unresolved issue is scale. Even after cuts, the expense ratio of about 4.3% of net assets is several multiples of typical larger LICs, and management itself describes operating costs as a significant headwind for a company of its size.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityJurisdictionOwnershipStatus

Underwood Capital Limited

Australia

Parent, ASX-listed

Active

Phytotech Medical (UK) Pty Ltd

United Kingdom

100%

Provided services to the parent; voluntarily wound up and deregistered 30 Dec 2025

Results by Segment and Segment Margins & Growth (%)

MetricFY2022FY2023FY2024FY2025FY2026

Total income (AUD K)

-16,338-2,5921,199937684

Profit before tax (AUD K)

-17,795-4,1639546-157

Total expenses (AUD K)

1,4571,5711,104890841

Total income YoY growth (%)

n/m

n/m

n/m

-21.9-27.0

Segment Revenue

SleeveFY2024 gain/(loss) AUD KFY2026 gain/(loss) AUD KFY2026 book value AUD K

Weed Me Inc. (legacy, unlisted, Canada)

361-1,8016,982

Delivra Health Brands (legacy, listed, Canada)

1,50200

Emerging Therapeutics Group (legacy, unlisted, Australia)

60100

Medio Labs (legacy, unlisted)

-1,95900

Listed ASX securities (HD-managed)

—2,48813,104

“—” = not publicly disclosed.

Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Total income ("revenue") AUD K

-16,338-2,5921,199937684

Interest and dividend income AUD K

—187206540427

Net unrealised gains/(losses) AUD K

—-2,7647621,529-698

Realised gains/(losses) AUD K

—-144-29-1,216955

Operating expenses AUD K

1,4571,5711,104890841

Gross profit AUD K (equals total income; no COGS)

-16,338-2,5921,199937684

Operating income / EBITDA proxy AUD K (equals PBT)

-17,795-4,1639546-157

Profit before tax AUD K

-17,795-4,1639546-157

Income tax (expense)/benefit AUD K

1,863179-226198351

Net profit after tax AUD K

-15,932-3,984-131243193

Basic EPS (cents)

-6.93-1.74-0.060.120.09

Diluted EPS (cents)

-6.93-1.74-0.060.120.09

Dividends per share (cents)

00000

Financial Analysis

MetricFY2023FY2024FY2025FY2026

Administration expenses AUD K

673494333283

Asset management expenses AUD K

189175211249

Employee and director expenses AUD K

654434348310

Share-based payments AUD K

55000

Total expenses AUD K

1,5711,104890841

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Net margin on total income (%)

n/m

n/m

-10.925.928.2

PBT margin on total income (%)

n/m

n/m

7.94.9-23.0

Expense ratio, opex / closing net assets (%)

6.08.15.74.64.3

Total income CAGR FY2022–FY2026

n/m

n/m

n/m

n/m

n/m

Share Count (millions) and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Total assets AUD K

26,35121,96421,89621,70821,261

Cash and cash equivalents AUD K

6,3193,715189534697

Financial assets at FVTPL AUD K

19,19517,47821,54320,73320,473

of which listed AUD K

—7876,77811,87013,491

of which unlisted (equity + debt) AUD K

—16,69014,7658,8636,982

Total debt (short + long) AUD K

00000

Net debt AUD K (negative = net cash)

-6,319-3,715-189-534-697

Deferred tax liability AUD K

—2,3292,5201,9491,753

Total liabilities AUD K

2,0012,5842,6812,4781,912

Total equity / net assets AUD K

24,35019,38019,21519,23019,349

Goodwill and intangibles AUD K

00000

Working capital AUD K (current assets less current liabilities)

—21,62921,66021,079—

Shares on issue (millions)

229.95210.31210.31205.74204.33

NTA per share, post-tax (cents)

10.599.189.109.309.46

Financial Analysis (FY2022–FY2026)

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow AUD K (includes investment purchases/sales)

—-1,528-3,489574236

Payments for financial assets AUD K

—-1,234-5,026-13,958-4,785

Proceeds from disposals AUD K

—351,59714,8195,155

Payments to employees and suppliers AUD K

—-1,347-1,168-911-832

Dividends and interest received AUD K

—329222540427

Capex AUD K

00000

Free cash flow AUD K (equals OCF; no capex)

—-1,528-3,489574236

Dividends paid AUD K

00000

Share buybacks AUD K

—1,0403522873

Net change in cash AUD K

—-2,568-3,524346163

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2022FY2023FY2024FY2025FY2026

ROE on closing equity (%)

-65.4-20.6-0.71.31.0

ROA on closing total assets (%)

-60.5-18.1-0.61.10.9

ROIC (%) (equals ROE; no debt)

-65.4-20.6-0.71.31.0

Current ratio (x)

—85.8135.540.8—

Debt / equity (x)

00000

Net debt / EBITDA (x)

n/m

n/m

n/m

n/m

n/m

Interest coverage (x)

n/m

n/m

n/m

n/m

n/m

Asset turnover, total income / total assets (x)

-0.62-0.120.050.040.03

Cash conversion cycle (days)

n/m

n/m

n/m

n/m

n/m

Price / NTA at 30 June (x)

0.600.460.510.490.57

Geographic Revenue

RegionFY2023FY2024FY2025FY2026

Canada (named holdings) AUD K

10,87811,5498,8636,982

Australia / ASX (named holdings) AUD K

3,9823,99311,87013,491

Finland (Valo Therapeutics) AUD K

50060000

Mixed or unallocated (other listed/unlisted, Medio Labs) AUD K

2,1175,40100

Total financial assets AUD K

17,47721,54320,73320,473

Revenue by Region (%)

RegionFY2023FY2024FY2025FY2026

Canada (%)

62.253.642.734.1

Australia (%)

22.818.557.365.9

Finland (%)

2.92.800

Mixed (%)

12.125.100

Share Price and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Share price at 30 June (AUD)

0.0640.0420.0460.0460.054

NTA per share (cents)

10.599.189.109.309.46

Discount to NTA (%)

39.654.249.550.542.9

Shares on issue (millions)

229.95210.31210.31205.74204.33

Market cap at 30 June (AUD Mn)

14.78.89.79.511.0

Share Price History

PeriodStart priceEnd priceReturn

1 year (Jun 2025 – Jun 2026)

0.0460.054+17.4%

3 years (Jun 2023 – Jun 2026)

0.0420.054+28.6%

5 years (Jun 2021 – Jun 2026)

0.0770.054-29.9%

7 years (Jun 2019 – Jun 2026)

0.2500.054-78.4%

Valuation Multiples

MultipleValue (FY2026)Comment

P/E

about 60x (5.4c / 0.09c)

Not meaningful for an LIC

Price / NTA (post-tax)

about 0.57x

Primary valuation metric

Price / pre-tax NTA

lower (pre-tax NTA exceeds post-tax by the DTL of about A$1.75m, about 0.86c per share)

Analyst estimate

Price / liquid assets per share

about 0.78x (5.4c vs about 6.9c of cash plus listed securities, pre-tax)

Market ascribes negative value to Weed Me and costs

P/B

about 0.57x

Equals P/NTA (no intangibles)

Capital Markets

ItemDetail

Dividend history

No dividends paid, recommended or declared in FY2022–FY2026

Dividend policy

Not formally published; FY2024 report notes available funds are affected by income tax and "HGV's dividend policy"

Franking balance

Nil at 30 Jun 2026 (A$82,319 at 30 Jun 2025; A$28,709 at 30 Jun 2024)

Buybacks

Unmarketable parcel Jun 2023 (19.64m shares, A$1.04m); FY2025 unmarketable parcel (4.57m shares, A$0.23m); on-market program Sep 2024 – Oct 2025 (up to 21.03m shares; about 0.4m bought in FY2026 for A$0.02m); on-market program from 10 Apr 2026 (up to about 20.53m shares; 1.80m bought by 30 Jun 2026 at A$0.0525 average); extension to 27 Oct 2026 reported

Cumulative reduction in share count

From 229.95m (Jun 2022) to 203.53m (Jul 2026), about -11.5%; the manager cites about 4% repurchased since its appointment (excluding the June 2023 parcel buyback)

Analyst Conclusions

Management guidance

No quantitative guidance is provided. Management states the portfolio's performance is materially dependent on global equity markets, that the buyback is expected to remain active while shares trade at a significant discount to NTA, and that Weed Me monetisation is being actively pursued.

Consensus

None. No sell-side coverage was identified.

Bull case

  1. Sum-of-the-parts underpinning: at about 5.4c, the share price is below the roughly 6.9c per share of cash and listed securities alone. Investors receive the Weed Me stake (book about 3.4c per share pre-tax), the tax assets and the manager's process for free. Even a sale of Weed Me at a 30% discount to book would release roughly 2.4c per share of cash.

  2. Proven manager in an aligned structure: a gross return of about 22.9% on listed capital in FY2026 and over 10% annualised ex-Weed Me NTA growth since July 2023, with the manager as the largest shareholder and the Chair buying.

  3. Self-help capital management: buybacks at about a 45% discount to NTA are mechanically accretive; continued cost reductions and potential Weed Me dividends could make the vehicle cash-neutral on running costs.

Bear case

  1. Structural sub-scale trap: about A$0.84m of costs on A$19m means roughly 4.3% annual drag; buybacks shrink the asset base and worsen the ratio. Without growth or a corporate event, the discount may never close.

  2. Weed Me is hard to sell: an unlisted, CAD-denominated stake in a sector trading at about 0.9x revenue; its value fell 21% in FY2026 despite record sales. Forced or delayed sale could crystallise losses.

  3. Tech-skewed concentration risk: a handful of ASX software and services names in a world of AI disruption uncertainty; the March 2026 quarter showed the portfolio can give back half-year gains rapidly.

Catalysts and monitorables (next 12 months)

Catalyst / monitorableTimingWhat to watch
2026 AGM26 Nov 2026Auditor ratification (Stannards); any shareholder pressure on discount; board renewal
Weed Me transactionAny timeSale price relative to the A$6.98m book
Monthly NTA releasesMonthlyTrajectory versus 9.46c; recovery of software holdings
Buyback execution and renewalProgram to Oct 2026 and beyondVolume repurchased; renewal at up to 10%
Half-year results to 31 Dec 2026Late Feb 2027Expense ratio; tax position; Weed Me valuation multiple
Substantial holder noticesOngoingAccumulation by HD Capital, Benjamin Graham, or activist LIC investors
Dividend policyFY2027Any reinstatement once franking credits are generated
IMA horizon30 Jun 2028Early signals on renewal or restructuring

Concluding analyst verdict

Underwood Capital is no longer the company described by the identifiers supplied for this research. The cannabis investment vehicle known as MMJ Group Holdings, and later Hygrovest, is effectively finished: of the roughly A$74 million once deployed into North American cannabis, only the Weed Me stake remains, carried at A$7.0 million. In its place sits a small, debt-free, value-oriented listed investment company run by an aligned external manager whose own record since July 2023 is credible — a cost base nearly halved, legacy assets realised at or above carrying value, and a listed book that returned about 23% gross in FY2026.

The investment debate, however, is not about the manager's stock-picking. It is about structure. At about A$19 million of net assets, the vehicle's fixed costs consume more than four percent of capital each year, the stock is illiquid, there is no dividend, and the market has refused to close a 40–55% discount to NTA for four consecutive years despite a dramatic improvement in portfolio quality. The share price sits below the value of liquid assets alone, which is an unusually strong margin of safety, but margins of safety only pay out when something forces the gap to close.

The two most plausible forcing events are a sale of the Weed Me stake, which management is now openly soliciting, and a more aggressive capital-return or corporate solution for the vehicle itself, for which there is no announcement. Buybacks help at the margin but are constrained by liquidity and slowly worsen the cost ratio.

Our assessment: asymmetric but catalyst-dependent. Downside appears limited by liquid asset backing and a clean balance sheet; upside requires either a Weed Me realisation near book or a structural resolution of sub-scale. Absent either within the next 12–24 months, the most likely outcome is continued modest NTA growth with a persistent discount. Monitor the 26 November 2026 AGM and any Weed Me announcement closely.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleAppointedBackgroundEducationShares held

Warwick Sauer

Independent Non-Executive Chair

NED 20 Mar 2023; Chair 1 Aug 2023

Corporate lawyer with 25 years' experience in commercial law, capital markets, M&A and litigation; 14 years at JLL including 7 years as General Counsel for JLL's A$4bn APAC business; director of a private investment company (previously described as investing in deep-value and "net/net" stocks); former director of BSA Limited

B.Com (financial accounting) and LLB, University of Queensland

3,223,787 (up from 1,242,010; bought 1,981,777 in FY2026)

David Prescott

Independent Non-Executive Director

20 Mar 2023

Founder and Managing Director of Lanyon Asset Management (value-oriented equities manager); 20+ years in investing and analysis in Australia and the UK; former Head of Equities at CP2 (formerly Capital Partners); former director of Lanyon Investment Company and BSA Limited

Economics, University of Adelaide; Grad Dip Applied Finance and Investment (FINSIA); CFA charterholder

Nil

Jason Byrne

Independent Non-Executive Director

1 Aug 2023

30+ years building businesses in wagering technology, digital place-based advertising, e-commerce, legal technology, apparel logistics, procurement technology and offshore development; director of Motio Limited (ASX: MXO)

—

Nil

“—” = not publicly disclosed.

Executive Leadership Team

NameRoleTenureBackgroundBase salary

James (Jim) Hallam

Chief Financial Officer and Company Secretary (sole employee)

CFO since 3 Apr 2018; Company Secretary since 22 Jun 2018

About 30 years in investment management with alternative asset managers including Hastings Funds Management and Annuity Australia; former responsible manager, investment manager and CFO roles

A$170,000 (reduced from A$225,000); 6-month termination benefit and notice period

Executive Leadership Team (Annual)

NameFY2025 totalFY2026 totalFY2026 composition

Warwick Sauer (Chair)

58,13354,806

Fees 48,934 + super 5,872

Jason Byrne

41,93338,600

Fees

David Prescott

41,93338,600

Fees

Jim Hallam (CFO/CoSec)

205,445178,490

Salary 154,034 + super 30,000 + leave movement (5,544)

Total KMP

347,444310,496

100% fixed; no STI, LTI or equity grants

Board & Management Changes

DateChangeContext

20 Mar 2023

Sauer and Prescott join the board

Value-investing and legal expertise added during the manager tender

1 Aug 2023

Peter Wall (Chair) and Doug Halley retire; Jason Byrne appointed; Sauer becomes Chair

Board reduced to three to cut costs; full break from the cannabis-era board

FY2023

Winton Willesee and Michael Curtis depart (received FY2023 fees)

Earlier board refresh

1 Dec 2023

Board and CFO voluntarily cut pay 10%

Cost program

Mar 2024 / Mar 2026

Auditor changes (BDO to Connect National Audit; then to Stannards)

Cost-driven audit tenders

Major Shareholders

RankHolderShares%
1

J P Morgan Nominees Australia Pty Limited

31,995,37815.72
2

BNP Paribas Nominees Pty Ltd (Clearstream)

12,074,7045.93
3

Mr Benjamin Youngman Graham (Graham Family A/C)

11,200,0005.50
4

Perpetual Corporate Trust Ltd (Affluence LIC Fund)

7,694,2133.78
5

Mr George Chien-Hsun Lu

6,817,7073.35
6

Mr Peter C Wall & Mrs Tanya-Lee Wall (Wall Family Super A/C)

4,500,0002.21
7

Maxlek Pty Ltd (Jims and Joels Super A/C)

4,425,0002.17
8

Jaindi Investments Pty Ltd

3,850,0001.89
9

BNP Paribas Nominees Pty Ltd (IB AU Noms Retail Client)

3,474,9291.71
10

Mrs Lily Mah (MJ A/C)

3,298,2401.62

Competitive Landscape

Key Competitors

Peer (ASX code)CategoryRelative positioning vs UWC

WAM Microcap (WMI)

Micro-cap LIC

Far larger, established dividend payer, trades nearer NTA

NAOS Small Cap Opportunities (NSC)

Concentrated small-cap LIC

Similar concentrated style; larger scale

Thorney Opportunities (TOP)

Activist / special situations

Closest in style (activist, discount to NTA)

Sandon Capital Investments (SNC)

Activist LIC

Activist value; dividend-paying

Glennon Small Companies (GC1)

Small-cap LIC

Comparable small scale; discount issues

Acorn Capital Investment Fund (ACQ)

Listed and unlisted micro-cap

Mixed listed/unlisted exposure, similar to UWC's legacy profile

Spheria Emerging Companies (SEC)

Small/micro-cap value

Larger; value style

Ophir High Conviction Fund (OPH)

Concentrated growth

Different style (growth)

Bailador Technology Investments (BTI)

Unlisted technology investor

Overlapping tech exposure; private-company focus

Affluence LIC Fund (unlisted; holder of UWC)

Fund-of-LICs

A shareholder that buys discounted LICs — a potential catalyst rather than a competitor

Competitor Detail

MetricUWC FY2026

Net assets

A$19.3m

NTA per share growth (FY2026)

+1.7%

Expense ratio

about 4.3% of net assets

Price / NTA

about 0.57x

Dividend yield

0%

Recent Developments

Monthly NTA announcements are lodged routinely; only those with confirmed figures are listed.

There were no guidance revisions, litigation, regulatory actions, layoffs or contract wins in the period (none disclosed).

Company Snapshot

1

Employees

2014

Founded

Sydney, Australia

Headquarters

SWOT Analysis

Strengths

  • Liquidity transformed: listed securities rose from A$0.79m (FY2023) to A$13.49m (FY2026); illiquids fell from 87% to under 35% of NTA (FY2026 manager letter).
  • Debt-free balance sheet: zero borrowings in every year FY2022–FY2026; no commitments or contingent liabilities at 30 June 2026.
  • Manager alignment: HD Capital holds 14% (substantial holder notice, June 2024) and describes itself as the largest shareholder.
  • Cost discipline: opex down 46% from A$1.57m (FY2023) to A$0.84m (FY2026); audit fees down from A$114k to A$52k.
  • Demonstrated realisation skill: Valo sold at 20% above carrying value; Sequoya recovered from a zero valuation; ETG sold at about 5.4x adjusted cost.
  • Strong HD-managed returns: about A$2.5m gains and about 22.9% gross return on opening listed capital in FY2026; ex-Weed Me NTA up from about 5c to about 6.8c (manager estimate, over 10% annualised).
  • Independent, experienced board: CFA-qualified fund manager (Prescott) and a former JLL APAC General Counsel (Sauer); 98% Remuneration Report support (2025 AGM).

Weaknesses

  • Sub-scale: net assets of about A$19.3m; operating costs are about 4.3% of net assets, described by the manager as a significant headwind.
  • Concentration in a single illiquid legacy asset: Weed Me at A$6.98m is about 36% of NTA and is Level 3 valued.
  • Weak headline earnings: NPAT of only A$0.19m in FY2026 and A$0.24m in FY2025; ROE of about 1%.
  • No dividends: none paid in FY2022–FY2026; franking account nil at 30 June 2026.
  • Persistent discount: price/NTA of about 0.46–0.57x every year FY2023–FY2026.
  • Key-person dependency: a single employee (CFO) and a two-principal manager.
  • Long-term record: NTA per share fell from about 20.5c (Mar 2021) to 9.46c (Jun 2026); cumulative NPAT FY2020–FY2026 of about -A$63.7m.

Opportunities

  • Weed Me sale: the stake (about 3.4c per share pre-tax) is effectively valued at zero by the market, since price is below liquid assets per share (about 6.9c); any sale near book would be highly accretive.
  • Accretive buybacks: each share repurchased at about 5.3c against 9.46c NTA adds value; the March 2026 program allows up to about 20.5m shares.
  • Software rebound: the two largest FY2026 detractors were unrealised and the manager kept buying.
  • Corporate action on the vehicle: a merger with another LIC, a capital return or a conversion could close the discount (no such action announced; speculative).
  • Tax assets: unrecognised trading tax losses of A$1.83m (DTA of A$0.46m not recognised) and capital losses of A$0.11m could shelter future gains.
  • Weed Me dividends: the investee paying cash distributions supports income and valuation.

Threats

  • Further cannabis de-rating: a 10% revenue change at Weed Me moves its value by about A$0.83m; the multiple already fell from 1.6x to 0.9x.
  • AI disruption of software investees: the March 2026 quarter showed the vulnerability of the tech-skewed portfolio.
  • Shareholder fatigue: unmarketable parcels, low liquidity and no dividends could lead to pressure for a wind-up at a discount to NTA.
  • FX risk: the Weed Me stake is CAD-denominated and unhedged.
  • Cost inflation: listing, audit and insurance costs are largely fixed against a shrinking asset base if buybacks continue.
  • Manager concentration: the IMA runs to 30 June 2028; any departure of key personnel would disrupt the strategy.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Sep 2024 (context)ETG sold for A$3.8m; on-market buyback (10%) announcedLargest legacy realisation under HD
Oct 2024 (context)Delivra stake sold for about C$1.1mLeaves Weed Me as the only significant legacy asset
12 Nov 2024 (context)October pre-tax NTA up 2% to 10.75c; post-tax NTA 9.60cBest result in four quarters at the time
22 Nov 2024 (context)2024 AGMRatified Connect National Audit; name change process
13 Dec 2024 (context)Name change to Underwood Capital; ticker UWCRebrand away from cannabis
FY2025Unmarketable-parcel buyback of 4.57m shares (A$0.23m)Register clean-up
30 Jun 2025FY2025 balance date: NTA 9.30c; Weed Me A$8.86m; listed A$11.87mPortfolio 57% ASX-listed
25 Aug 2025FY2025 Appendix 4E and Annual Report: profit A$0.24mFirst full-year profit under HD (note: an auto-generated InvestSMART summary erroneously describes UWC as a precision engineering company paying a dividend; this is incorrect and should be disregarded)
Oct 2025First on-market buyback expires (about 0.4m shares bought in FY2026 under it)Limited liquidity constrained execution
FY2025 AGM (Nov 2025)98% support for Remuneration ReportStrong shareholder endorsement
30 Dec 2025Phytotech Medical (UK) deregisteredSimplification; single-entity reporting
31 Dec 2025Half-year NTA 10.89c (up from 9.30c)Peak NTA under HD
26 Feb 2026Half-year report: revenue up 356%, profit after tax up 460% vs pcpStrong H1 from listed book
Q3 FY2026 (Jan–Mar 2026)Software sell-off ("SaaSpocalypse") erodes H1 gainsTwo largest detractors were mark-to-market, not realised; manager kept buying
Mar 2026Stannards Audit appointed auditorCost/administrative
24 Mar 2026New on-market buyback announced (up to about 20.5m shares, from 10 Apr 2026)Capital management at a deep discount
Apr–Jun 20261,796,057 shares bought back at average A$0.0525About 0.9% of capital retired
–Weed Me pays a dividend after record sales, per its CEOValidates asset quality even as its book value falls
29 Jun 2026Benjamin Graham becomes substantial holder (6.12%)New significant shareholder
30 Jun 2026FY2026 balance date: NTA 9.46c; Weed Me A$6.98m; listed A$13.49mIlliquids about 34% of portfolio
21 Jul 2026Shares on issue 203,530,807; 2,623 holdersRegister continues to shrink
25 Aug 2026FY2026 Appendix 4E: profit A$0.19m (-21%); revenue A$0.68m (-27%); opex A$0.84mSteady but sub-scale
25 Aug 2026Manager letter invites bids for the Weed Me stake; notes shares trade below liquid assetsExplicit monetisation push
Aug–Sep 2026Buyback update: extended to 27 Oct 2026 (TipRanks)Ongoing capital return
1 Sep 2026Annual Report to shareholders lodgedFormal filing
26 Nov 2026 (upcoming)2026 AGM; director nominations closed 8 Oct 2026Watch for auditor ratification and any board-renewal resolutions

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

2 charts
Results by Segment: Total income rose from AUD -16.3 Mn in FY2022 to AUD 0.7 Mn in FY2026.
Hygrovest Limited — Results by Segment
Series (AUD Mn)FY2022FY2023FY2024FY2025FY2026
Total income-16.3-2.61.20.90.7
Total expenses1.51.61.10.90.8
Profit before tax-17.8-4.20.10-0.2

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Hygrovest Limited, Annual Report for the year ended 30 June 2024 (ASX, 30 Aug 2024).
  2. Underwood Capital Limited, Appendix 4E and Annual Report for the year ended 30 June 2026 (ASX, 25 Aug 2026; Annual Report lodged 1 Sep 2026).
  3. Underwood Capital Limited, Half-Year Financial Report to 31 December 2025 (ASX, 26 Feb 2026) and InvestSMART summary.
  4. Hygrovest Limited, ASX announcement: Sale of Shares in Emerging Therapeutics Group Pty Ltd (24 Sep 2024).
  5. MMJ Group Holdings Limited, Annual Report for the year ended 30 June 2021.
  6. Proactive Investors: Hygrovest company page; October 2024 NTA report; September 2024 update; name-change article (Dec 2021).
  7. Market Index: HGV company overview (former names, listing date, auditor).
  8. Stockhead: Phytotech sale and Harvest One sell-down articles (2018); MMJ investment record (2020).
  9. iTWire (April 2021); Benzinga (July 2021); Newsfile (Harvest One renamed Delivra, June 2022).
  10. ROIC.ai, Finnomena, Pearler, TipRanks, Barchart, FNN (aggregators; used only where flagged).

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.